Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PTHL NASDAQ:SINT NASDAQ:STRR NASDAQ:TTOO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePTHLPheton$0.89+0.6%$15.55$0.60▼$32.00$5.87MN/A869,882 shs666,227 shsSINTSintx Technologies$2.68-0.4%$2.97$1.71▼$8.60$7.39M0.65644,912 shs24,612 shsSTRRStar Equity$2.01+0.5%$2.04$1.72▼$4.74$6.49M0.9420,120 shs788 shsTTOOT2 Biosystems$0.02-48.5%$0.11$0.00▼$4.17$358K0.25548,222 shs983 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePTHLPheton-11.25%-19.32%-95.46%-81.47%+88,749,900.00%SINTSintx Technologies+1.51%+4.26%-17.48%+6.32%-41.65%STRRStar Equity+2.02%-3.81%+3.59%-14.04%-49.50%TTOOT2 Biosystems+112.90%+117.11%-75.56%-77.29%-99.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPTHLPhetonN/AN/AN/AN/AN/AN/AN/AN/ASINTSintx Technologies2.3643 of 5 stars3.52.00.00.02.21.70.6STRRStar Equity2.67 of 5 stars3.54.00.00.00.01.71.3TTOOT2 BiosystemsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePTHLPheton 0.00N/AN/AN/ASINTSintx Technologies 3.00Buy$28.00944.78% UpsideSTRRStar Equity 3.00Buy$5.00148.76% UpsideTTOOT2 Biosystems 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TTOO, STRR, SINT, and PTHL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025SINTSintx TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.005/15/2025STRRStar EquityMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPTHLPheton$448.20K13.11N/AN/A$0.94 per share0.95SINTSintx Technologies$1.23M6.01N/AN/A$2.90 per share0.92STRRStar Equity$53.36M0.12$0.33 per share6.07$10.98 per share0.18TTOOT2 Biosystems$7.68M0.05N/AN/A($6.91) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePTHLPheton-$660KN/A0.00∞N/AN/AN/AN/AN/ASINTSintx Technologies-$11.02M-$50.56N/A∞N/A-483.85%-203.66%-104.76%8/12/2025 (Estimated)STRRStar Equity-$10.44M-$3.43N/AN/AN/A-16.43%-8.24%-3.48%8/13/2025 (Estimated)TTOOT2 Biosystems-$50.08MN/A0.00∞N/A-563.16%N/A-174.06%10/6/2025 (Estimated)Latest TTOO, STRR, SINT, and PTHL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025STRRStar Equity-$0.26N/AN/AN/A$16.75 millionN/A8/12/2025N/ASINTSintx Technologies-$0.79N/AN/AN/AN/AN/A5/15/2025Q1 2025SINTSintx Technologies-$0.71-$1.29-$0.58-$1.29$0.73 million$0.37 million5/14/2025Q1 2025STRRStar Equity-$0.25-$0.52-$0.27-$0.37$16.35 million$12.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPTHLPhetonN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ASTRRStar EquityN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPTHLPhetonN/A12.3912.17SINTSintx TechnologiesN/A3.443.25STRRStar Equity0.221.420.88TTOOT2 BiosystemsN/A0.400.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPTHLPhetonN/ASINTSintx Technologies18.38%STRRStar Equity3.84%TTOOT2 Biosystems23.18%Insider OwnershipCompanyInsider OwnershipPTHLPhetonN/ASINTSintx Technologies4.08%STRRStar Equity33.51%TTOOT2 Biosystems0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePTHLPheton116.58 millionN/AN/ASINTSintx Technologies402.76 million2.64 millionNot OptionableSTRRStar Equity4603.23 million2.15 millionNot OptionableTTOOT2 Biosystems18021.04 million21.04 millionOptionableTTOO, STRR, SINT, and PTHL HeadlinesRecent News About These CompaniesShort Interest in T2 Biosystems, Inc. (NASDAQ:TTOO) Expands By 1,146.7%August 4 at 2:21 AM | americanbankingnews.comT2 Biosystems (NASDAQ:TTOO) versus Retractable Technologies (NYSE:RVP) Financial ContrastAugust 3, 2025 | americanbankingnews.comTTOO T2 Biosystems, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comT2 Biosystems Inc. (TTOO) After Hours QuoteJune 10, 2025 | nasdaq.comDespite Promising Technology, Did Operational Cost Structure Take Down T2 Biosystems?March 5, 2025 | 360dx.com3T2 Biosystems initiates major layoffs, seeks asset saleFebruary 22, 2025 | uk.investing.comMedical diagnostics firm T2 Biosystems cuts ‘substantially all’ workersFebruary 18, 2025 | bizjournals.comT2 Biosystems to be delisted from NasdaqFebruary 11, 2025 | msn.comT2 Biosystems stock plunges to 52-week low of $0.22January 30, 2025 | msn.comT2 Biosystems Inc’s Stock Drama: Could This Be a Game-Changer for TTOO Investors?January 24, 2025 | bovnews.comBT2 Biosystems stock plunges to 52-week low of $0.25January 21, 2025 | msn.comT2 Biosystems amends loan terms, extends maturity dateJanuary 18, 2025 | msn.comT2 Biosystems reports preliminary Q4 revenue $2.3MJanuary 7, 2025 | markets.businessinsider.comT2 Biosystems Reports Preliminary Financial Results For Q4 And Full Year 2024January 7, 2025 | markets.businessinsider.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial ResultsJanuary 7, 2025 | finance.yahoo.comT2 Biosystems Enhances Governance and Leadership StabilityJanuary 3, 2025 | tipranks.comT2 Biosystems announces sale of four T2Dx Intruments to European distributorDecember 18, 2024 | markets.businessinsider.comT2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European DistributorDecember 18, 2024 | finance.yahoo.comT2 Biosystems achieves milestone with 250,000th novel sepsis test shippedDecember 17, 2024 | markets.businessinsider.comT2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped GloballyDecember 17, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTTOO, STRR, SINT, and PTHL Company DescriptionsPheton NASDAQ:PTHL$0.89 +0.00 (+0.55%) Closing price 04:00 PM EasternExtended Trading$0.89 -0.01 (-0.61%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.Sintx Technologies NASDAQ:SINT$2.68 -0.01 (-0.37%) Closing price 03:59 PM EasternExtended Trading$2.69 +0.01 (+0.37%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.Star Equity NASDAQ:STRR$2.02 +0.02 (+0.75%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Star Equity Holdings, Inc. engages in the construction business in the United States and internationally. It operates through two segments: Construction, and Investments. It manufactures modular housing units, structural wall panels, permanent wood foundation systems, and other engineered wood products; supplies general contractors with building materials; holds real estate assets; and manages investments. The company was formerly known as Digirad Corporation and changed its name to Star Equity Holdings, Inc. in December 2020. Star Equity Holdings, Inc. was founded in 1985 and is headquartered in Old Greenwich, Connecticut.T2 Biosystems NASDAQ:TTOO$0.02 -0.02 (-48.48%) As of 03:20 PM EasternT2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
